IdeaSphere looks to strengthen and expand its international healthcare business through its acquisition of Boehringer Ingelheim's Pharmaton multivitamin business, the brand management firm states Aug. 25 in a joint release announcing the deal. The purchase "complements not only our geographical strength in North America with attractive market positions but also provides access to other strategic markets for IdeaSphere in Europe, the Middle East, Latin America and Asia. Moreover, both of our companies emphasize science-based medicines," said IdeaSphere President and COO Mark Fox. Twinlab-owner IdeaSphere acquired Metabolife in November and received worldwide licensing rights to Weil Nutritional Supplements in January (1"The Tan Sheet," Nov. 14, 2005, In Brief and 2"The Tan Sheet, Jan. 23, 2006, In Brief). "Boehringer Ingelheim will continue to strengthen is Consumer Healthcare business by further building up the flagship and international core brands, e.g., Dulcolax, Buscopan and Antistax," Chairman of the Board of Managing Directors Alessandro Banchi noted in the release...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
